Premium
PIII‐34
Author(s) -
Marunde R.,
Jin Y.,
Ayaji O.,
Neville K.,
Phillips S.,
Skaar T. C.,
Hall S. D.
Publication year - 2006
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2005.12.242
Subject(s) - genotype , cyp3a5 , blood pressure , single nucleotide polymorphism , haplotype , population , allele , medicine , biology , genetics , gene , environmental health
BACKGROUND/AIMS Previous reports suggest that cytochrome P450 3A5 (CYP3A5) expression is associated with hypertension. We examined whether this association is also present in a group of young Nigerian males. METHODS DNA samples and blood pressure data were collected from 106 Nigerian males. Blood pressure was determined by manual sphygmomanometry. CYP3A5*3, *6 and *7 single nucleotide polymorphisms (SNPs) were identified using real time PCR. Four common haplotypes were constructed from the SNP data: *1, *3, *6, *7 with PHASE II. Based on the haplotype, subjects were classified into homozygote expressors (*1/*1), heterozygote expressors (*1/*0) and nonexpressors (*0/*0). Clinical characteristics among subjects with different CYP3A5 genotypes were compared with ANOVA using SPSS. RESULTS Allele frequencies for *1, *3, *6 and *7 in this Nigerian population are 56.4%, 15.8%, 9.4% and 14.9%, respectively. We did not detect any difference in systolic, diastolic and mean arterial blood pressure between CYP3A5 genotypes (table 1). CONCLUSION In addition to the CYP3A5*3 allele, the non‐expressing *6 and *7 alleles were very prevalent in this Nigerian population. We did not identify any association between the CYP3A5 genotypes and blood pressure in this population.Clinical Characteristics Based on CYP3A5 Genotype CYP3A5 genotype Age BMI SBP DBP MAP*1/*1 (N=35) 23.3 ± 10.2 22.0 ± 14.4 114 ± 9.6 70.2 ± 9.6 84.8 ± 2.6 *1/*0 (N=55) 23.8 ± 10.5 21.9 ± 13.8 111.1 ± 11.3 71.3 ± 11.2 84.6 ± 2.8 *0/*0 (N = 16) 23.4 ± 9.5 21.4 ± 10.4 113.5 ± 6.8 75.1 ± 6.7 87.8 ± 2.7 P value 0.68 0.81 0.59 0.29 0.53Clinical Pharmacology & Therapeutics (2005) 79 , P67–P67; doi: 10.1016/j.clpt.2005.12.242